Today: 31 January 2026
Subscribe
Browse Category

Healthcare News 29 October 2025 - 19 November 2025

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire cancer diagnostics specialist Exact Sciences, in what could be the healthcare giant’s largest deal in nearly a decade and a major shake-up for the global cancer testing market. Bloomberg Abbott in Talks for Biggest Deal in Nearly a Decade On Wednesday, November 19, 2025, multiple outlets reported that Abbott Laboratories is close…
19 November 2025
····
LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss market LifeMD Announces $199 Cash-Pay Pricing for Wegovy and Ozempic This morning, LifeMD, Inc. (NASDAQ: LFMD) unveiled what it calls…
17 November 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the $920–$970B range, reflecting price swings and share count. On trailing metrics the stock trades near 50x earnings; on Lilly’s 2025…
15 November 2025
····
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight today after the company and its partner Johnson & Johnson announced they will discontinue a…
14 November 2025
····
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial for Alcohol Use Disorder (AUD) to Hadassah Medical Center in Jerusalem. GlobeNewswire At the same time, Clearmind filed a new…
13 November 2025
····
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc. (NASDAQ: MGRX), the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy. GlobeNewswire What Mangoceuticals announced today In a press release and…
13 November 2025
···
Scott Bessent Faces Fresh Scrutiny Over Medicare‑Tax ‘Limited Partner’ Loophole and an Unkept Back‑Taxes Pledge — What’s New on Nov. 12, 2025

Scott Bessent Faces Fresh Scrutiny Over Medicare‑Tax ‘Limited Partner’ Loophole and an Unkept Back‑Taxes Pledge — What’s New on Nov. 12, 2025

Treasury Secretary Scott Bessent is back under the microscope over his past use of a Medicare self‑employment tax loophole commonly claimed by hedge‑fund managers and other partnership owners. Senate Democrats have alleged since January that Bessent avoided roughly $900,000 in Medicare taxes by classifying himself as a limited partner of his own fund, Key Square Group—an approach the IRS has…
12 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader…
6 November 2025
··
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the day Stockanalysis. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6%…
4 November 2025
····
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases Gurufocus. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S. Gurufocus. The company’s strategy centers on leveraging its expertise…
3 November 2025
····
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecast Investing. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly…
30 October 2025
···
VSee Health (VSEE) Stock Rockets 75% on $10M Hospital Teleradiology Deal – Is This Telehealth’s Next Big Winner?

VSee Health (VSEE) Skyrockets 200% on Federal Telehealth Approval – Will the Surge Last?

Stock soars on federal approval, then steadies at new highs VSee Health’s stock (NASDAQ: VSEE) has experienced a whirlwind rally over the past two trading days. On October 28, shares of the telehealth upstart skyrocketed on news of a coveted federal security certification. The price leapt from just $0.62 at Monday’s close to as high as $2.52 during Tuesday’s intraday…
29 October 2025
··
1 … 7 8 9 10 11 12

Stock Market Today

  • CSG Share Price Drops 7% Amid Market Uncertainty, Valued Below Fair Price
    January 31, 2026, 4:16 PM EST. CSG (ENXTAM:CSG) shares fell 7% over the past week, closing at €30.56, reflecting cooling momentum. The current price is well below a narrative fair value of €55, based on the company's ammunition focus and defense sector prospects. CSG is a key ammunition supplier for European NATO countries, supporting Ukraine, yet limited public financial data and recent IPO volatility cast uncertainty over valuation. Analyst Marek Trnka highlights assumptions around margins and future earnings multiples influencing this gap. Risks include reduced demand from Ukraine or accelerated peace talks impacting contract visibility. Investors are advised to consider these factors and compare defense sector peers like Rheinmetall before reassessing CSG's market standing.
Go toTop